Male Diabetic Sexual Impotence: Effects of Dopaminergic Agents

Abstract

A double blind study was camed out with placebo and dopaminergic agents in 100 patients with male diabetic sexual impotence. In basal conditions, mean serum FSH, LH, PRL, and T levels did not significantly differ from those found in a normal control group. No significant variations with the exception of PRL reduction were observed after use of the dopaminergic agents. Sexual activity was improved in 50% of cases after 3-4 dihidroxifenilalanine and 10% of those of the phcebo group. In patients with bromocriptine, 20% improved their sexual function without changes in those receiving placebo.

Apomorphine, systèmes dopaminergiques centraux et contrôle de l’érection

“…Des patients diab6tiques souffrant de dysfonctions 6rectiles rapportent une am61ioration de l'6rection lorsqu'ils sont trait6s avec l'apomorphine [108]. Chez le rat, des r6sultats contradictoires ont 6t6 obtenus.…”

Differential behavioral response to dopamine D₂ agonists by sexually naive, sexually active, and sexually inactive male rats.

“…Although drug-induced effects in animal models do not always correspond to clinical findings, intriguing similarities exist between humans and animals in their responses to dopaminergic compounds. For example, in rats and humans, DA agonists enhance certain aspects of sexual behavior (Ahlenius, Larsson, & Svensson, 1980; Barbeu, 1969; Benassi-Benelli & Ferrari, 1979; Ferrari & Giuliani, 1995a; Hull et al, 1986; Melis & Argiolas, 1995; Pierini & Nusimovich, 1981), whereas DA blocking agents impair it (Ahlenius & Larsson, 1990). In the rat, administration of several DA D 2 agonists decreases the number of intromissions preceding ejaculation and ejaculation latency (Benassi-Benelli & Ferrari, 1979; Bitran, Thompson, Hull, & Sachs, 1989; Ferrari, Baggio, & Mangiafico, 1985; Ferrari & Giuliani, 1995a; Foreman & Hall, 1987), thus facilitating ejaculation.…”